These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 9024708)

  • 21. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
    Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
    Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
    Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].
    Yu GZ; Zhu MH; Chen Y; Ni CR; Li FM
    Ai Zheng; 2005 Nov; 24(11):1398-403. PubMed ID: 16552971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
    Ruggeri B; Zhang SY; Caamano J; DiRado M; Flynn SD; Klein-Szanto AJ
    Oncogene; 1992 Aug; 7(8):1503-11. PubMed ID: 1630814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
    Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
    Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic p53 mutation in a chemically induced hamster pancreatic ductal adenocarcinoma.
    Chang KW; Mangold KA; Hubchak S; Laconi S; Scarpelli DG
    Cancer Res; 1994 Jul; 54(14):3878-83. PubMed ID: 8033110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
    Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
    Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
    Shi Y; Zou M; Farid NR; al-Sedairy ST
    Br J Cancer; 1996 Nov; 74(9):1336-41. PubMed ID: 8912526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions.
    Ahomadegbe JC; Barrois M; Fogel S; Le Bihan ML; Douc-Rasy S; Duvillard P; Armand JP; Riou G
    Oncogene; 1995 Mar; 10(6):1217-27. PubMed ID: 7700647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
    Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
    Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
    Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
    Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival.
    Sessa F; Bonato M; Bisoni D; Ranzani GN; Capella C
    Eur J Histochem; 1998; 42 Spec No():67-76. PubMed ID: 10076772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
    Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
    J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.